The Goldman Sachs Group Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $36.00

Apellis Pharmaceuticals (NASDAQ:APLS) had its target price reduced by The Goldman Sachs Group from $71.00 to $36.00 in a report released on Wednesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. UBS Group dropped their price objective on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $25.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday, November 4th. Needham & Company LLC dropped their price target on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Oppenheimer lowered their price objective on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday. Six equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.06.

Apellis Pharmaceuticals Trading Up 4.3 %

Shares of APLS stock opened at $29.98 on Wednesday. Apellis Pharmaceuticals has a 1 year low of $24.34 and a 1 year high of $73.80. The firm has a market capitalization of $3.65 billion, a PE ratio of -10.94 and a beta of 0.87. The stock has a fifty day moving average of $31.02 and a two-hundred day moving average of $37.02. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.18 and a current ratio of 5.08.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The company had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The business’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.17) EPS. As a group, research analysts expect that Apellis Pharmaceuticals will post -1.4 EPS for the current year.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the sale, the director now owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 6.80% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in APLS. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Apellis Pharmaceuticals during the 1st quarter valued at $3,218,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Apellis Pharmaceuticals during the first quarter valued at about $89,000. Oppenheimer Asset Management Inc. lifted its position in shares of Apellis Pharmaceuticals by 8.3% in the first quarter. Oppenheimer Asset Management Inc. now owns 8,694 shares of the company’s stock worth $511,000 after buying an additional 664 shares during the last quarter. Lisanti Capital Growth LLC boosted its stake in shares of Apellis Pharmaceuticals by 92.7% during the 1st quarter. Lisanti Capital Growth LLC now owns 89,210 shares of the company’s stock worth $5,244,000 after acquiring an additional 42,905 shares in the last quarter. Finally, Sei Investments Co. increased its holdings in shares of Apellis Pharmaceuticals by 57.4% during the 1st quarter. Sei Investments Co. now owns 39,864 shares of the company’s stock valued at $2,343,000 after acquiring an additional 14,531 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).